Precision medicine path at personalized medicine research center/endocrinology and metabolism research institute: A systematic review

Abstract

Background

Precision medicine is an evolving predictive, early preventive, and treatment method that takes into account human gene heterogeneity for each individual. Personalized Medicine Research Center (PMRC) of Endocrinology and Metabolism Research Institute (EMRI) has been officially founded by the authority of the Ministry of Health and Medical Education on 18 December 2016 with the primary purpose of research, education, and dissemination of the personalized medicine approach throughout the country. In this review, we aimed to introduce the Personalized Medicine Research Center activities in the field of precision medicine since the establishment.

Methods

We systematically reviewed PubMed, Scopus, and WoS from 2016 to December 2019 to identify our relevant topics with PMRC affiliation.

Results

After screening processes, a total of 18 studies met eligibility criteria to include in the systematic review.

Conclusions

Personalized medicine that interchangeably called precision medicine is a new concept in medicine, the implementation of which needs to organize some infrastructures which are physical and the required education for healthcare professionals in different countries.

This is a preview of subscription content, access via your institution.

Fig. 1

Data availability

Not applicable.

Abbreviations

NCDs:

Non-communicable disease

T2DM:

Type 2 diabetes mellitus

WHO:

World Health Organization

PMRC:

Personalized medicine research center

EMRI:

Endocrinology and Metabolism Research Institute

WoS:

Web of Science

SNPs:

Single nucleotide polymorphisms

CNV:

copy number variation

References

  1. 1.

    Aghaei Meybodi HR, Hasanzad M, Larijani B. Path to personalized medicine for Type 2 Diabetes Mellitus: reality and hope. Acta Med Iran. 2017;55(3):166–74.

    PubMed  Google Scholar 

  2. 2.

    Hasanzad M, Sarhangi N, Aghaei Meybodi HR, Nikfar S, Khatami F, Larijani B. Precision medicine in non communicable diseases. Int J Mol Cell Med. 2019;8(2):0.

    Google Scholar 

  3. 3.

    Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff. 2018;37(5):694–701.

    Article  Google Scholar 

  4. 4.

    Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–34.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Khatami F, Larijani B, Nikfar S, Hasanzad M, Fendereski K, Tavangar SM. Personalized treatment options for thyroid cancer: current perspectives. Pharmgenomics Pers Med. 2019;12:235–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364(12):1144–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Arjmand B, Abdollahi M, Larijani B. Precision medicine: A new revolution in healthcare system. Iran Biomed J. 2017;21(5):282–3.

    PubMed  Google Scholar 

  8. 8.

    Peykari N, Larijani B. A multi-sectoral approach to combatting non-communicable diseases: Iran’s experience. J Diabetes Metab Disord. 2019;18(2):719–20.

    PubMed  PubMed Central  Article  Google Scholar 

  9. 9.

    Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–88.

    Article  Google Scholar 

  10. 10.

    Bennett JE, Stevens GA, Mathers CD, Bonita R, Rehm J, Kruk ME, et al. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 2018;392(10152):1072–88.

    Article  Google Scholar 

  11. 11.

    Arjmand B, Larijani B. Personalized medicine: A new era in endocrinology. Acta Med Iran. 2017;55(3):142–3.

    PubMed  Google Scholar 

  12. 12.

    Arjmand B, Abdollahi M, Larijani B. Study break: precision medicine: a new revolution in healthcare system. Iran Biomed J. 2017;21(5):282–3.

    PubMed  Google Scholar 

  13. 13.

    Erfani T, Sarhangi N, Afshari M, Abbasi D, Meybodi HRA, Hasanzad M. KCNQ1 common genetic variant and type 2 diabetes mellitus risk. J Diabetes Metab Disord. 2020;19(1):47–51.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Samimi H, Haghpanah V. Gut microbiome and radioiodine-refractory papillary thyroid carcinoma pathophysiology. Trends Endocrinol Metab. 2020;27(1–2):14–22.

    Google Scholar 

  15. 15.

    Mahdiannasser M, Haghpanah V, Damavandi E, Kabuli M, Tavangar SM, Larijani B, et al. Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas. Mol Biol Rep. 2020;47(3):2161–9.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Khooshemehri P, Jamaldini SH, Ziaee SAM, Afshari M, Sattari M, Narouie B, et al. Genetic polymorphism of mismatch repair genes and susceptibility to prostate cancer. Urol J. 2020;17(3):271–5.

    PubMed  Google Scholar 

  17. 17.

    Montazeri V, Ghahremani MH, Montazeri H, Hasanzad M, Safavi M, Ayati M, et al. A preliminary study of NER and MMR pathways involved in chemotherapy response in bladder transitional cell carcinoma: Impact on progression-free survival. Iran J Pharm Res. 2020;19(1):355–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Saki N, Sarhangi N, Afshari M, Bandarian F, Aghaei Meybodi HR, Hasanzad M. MTNR1B common genetic variant is associated with type 2 diabetes mellitus risk. Gene Rep. 2020;20:100695.

    Article  Google Scholar 

  19. 19.

    Afshardoost S, Sarhangi N, Afshari M, Aghaei Meybodi HR, Hasanzad M. The influence of a genetic variant in the KCNQ1 gene on type 2 diabetes mellitus development. Gene Rep. 2019;17:100529.

    Article  Google Scholar 

  20. 20.

    Motamedi RK, Sarhangi N, Afshari M, Sattari M, Jamaldini SH, Samzadeh M, et al. Kallikarein-related peptidase 3 common genetic variant and the risk of prostate cancer. J Cell Biochem. 2019;120(9):14822–30.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Rashidi BH, Sarhangi N, Aminimoghaddam S, Haghollahi F, Naji T, Amoli MM, et al. Association of vascular endothelial growth factor (VEGF) Gene polymorphisms and expression with the risk of endometriosis: a case-control study. Mol Biol Rep. 2019;46(3):3445–50.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Hasanzad M, Larijani B. The pathway from gene therapy to genome editing: A nightmare or dream. Int J Mol Cell Med. 2019;8(2):69–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Sarhangi N, Mohseni S, Aminimoghaddam S, Hossein Rashidi B, Haghollahi F, Qorbani M, et al. The association analysis of vascular endothelial growth factor – 2549 insertion/ deletion variant and endometriosis risk. Int J Mol Cell Med. 2019;8(Suppl1):63–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Azizi SM, Sarhangi N, Afshari M, Abbasi D, Aghaei Meybodi HR, Hasanzad M. Association analysis of the HNF4A common genetic variants with Type 2 diabetes mellitus risk. Int J Mol Cell Med. 2019;8(Suppl1):56–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Asgarbeik S, Mohammad Amoli M, Enayati S, Bandarian F, Nasli-Esfahani E, Forouzanfar K, et al. The role of ERRFI1 + 808T/G polymorphism in diabetic nephropathy. Int J Mol Cell Med. 2019;8(Suppl1):49–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Mirfeizi M, Hasanzad M, Sattari M, Afshari M, Abbasi D, Ajoodani Z, et al. Association of eNOS and ACE gene polymorphisms as a genetic risk factor in gestational diabetes in Iranian women. J Diabetes Metab Disord. 2018;17(2):123–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Sattari M, Hassanzad M, Jamaldini SH, Najafi A, Imani M, Mohammadhassani M, et al. Association between matrix metaloproteinases 2-1306C/T polymorphism and the risk of coronary artery disease in Iranian population. Pathophysiology. 2017;24(3):185–9.

    CAS  PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

MH has developed the project and written the manuscript with a collaboration by NS; SHN provided some guidance to the research; and BL designed the project and revised the manuscript. All authors read and approved the final version of manuscript before submission.

Corresponding authors

Correspondence to Mandana Hasanzad or Bagher Larijani.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interests.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sarhangi, N., Nikfar, S., Hasanzad, M. et al. Precision medicine path at personalized medicine research center/endocrinology and metabolism research institute: A systematic review. J Diabetes Metab Disord (2021). https://doi.org/10.1007/s40200-020-00708-9

Download citation

Keywords

  • Personalized Medicine Research Center
  • EMRI
  • Precision medicine
  • Personalized medicine